Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hengagliflozin for type 2 diabetes mellitus with mild cognitive impairment
ChiCTR2400083652Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Anhui Medical University
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Hengagliflozin treatment group with Placebo group (2 arms). Primary endpoints: Serological indicators related to cognitive function, Brain MRI scan and 2 more. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
henagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2400083652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083652.